SCHEMBL20257530

SCHEMBL20257530

Cc1cccc(Cc2ccc(C#N)cc2)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LOXL2 Q9Y4K0 2/20 0.48
CYP11B1 P15538 1/20 0.48
CYP11B2 P19099 1/20 0.48
CYP2A6 P11509 2/20 0.47
KDM4E B2RXH2 2/20 0.47
ALDH1A1 P00352 1/20 0.47
IDH1 O75874 2/20 0.47
LTA4H P09960 1/20 0.46
VNN1 O95497 1/20 0.44
SAE1 Q9UBE0 2/20 0.44
UBA2 Q9UBT2 2/20 0.44
IDO1 P14902 3/20 0.43
TAAR1 Q96RJ0 1/20 0.43
KCNH2 Q12809 1/20 0.42
SCN10A Q9Y5Y9 1/20 0.42
BCHE P06276 1/20 0.42
ACHE P22303 1/20 0.42
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8093804 0.84 TAAR1 (0.56) IDH1LTA4HSAE1UBA2IDO1
SCHEMBL8992963 0.82 LTA4H (0.46) KDM4ELTA4HSAE1UBA2IDO1
SCHEMBL8085716 0.81 CALM1 (0.55) IDH1LTA4HSAE1UBA2IDO1
SCHEMBL14346503 0.81 CYP2A6 (0.73) LOXL2CYP11B1CYP11B2CYP2A6ALDH1A1
SCHEMBL11087087 0.81 LTA4H (0.53) IDH1LTA4HSAE1UBA2IDO1
M-Xylene SCHEMBL28366327 0.80 CYP2A6 (0.64) LOXL2CYP11B1CYP11B2CYP2A6ALDH1A1
SCHEMBL29459538 0.80 TAAR1 (0.60) ALDH1A1LTA4HIDO1TAAR1ACHE
SCHEMBL30000562 0.80 TAAR1 (0.60) ALDH1A1LTA4HIDO1TAAR1ACHE
SCHEMBL1263547 0.80 TAAR1 (0.60) ALDH1A1LTA4HIDO1TAAR1ACHE
SCHEMBL28862319 0.79 LOXL2 (0.47) LOXL2CYP2A6SAE1UBA2IDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10227362-B2 Anti-pulmonary tuberculosis nitroimidazole derivative MEDSHINE DISCOVERY INC. (CN) 2019-03-12 US disclosed
US-20180162878-A1 ANTI-PULMONARY TUBERCULOSIS NITROIMIDAZOLE DERIVATIVE MEDSHINE DISCOVERY INC. (CN) 2018-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180162878-A1 ANTI-PULMONARY TUBERCULOSIS NITROIMIDAZOLE DERIVATIVE NDUFV1, NDUFV2, MT-ND4 LOXL2 3321/4885CYP11B1 241/4885CYP11B2 192/4885
US-10227362-B2 Anti-pulmonary tuberculosis nitroimidazole derivative NDUFV1, NDUFV2, MT-ND4 LOXL2 3321/4885CYP11B1 241/4885CYP11B2 192/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.